Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience.

Kerbage F, Sakr R, Lapierre V, Alexandrova K, Coman T, Leroux S, Lucas N, Pilorge S, Solary E, Bourhis JH, Castilla-Llorente C.

Clin Lymphoma Myeloma Leuk. 2020 Jan 2. pii: S2152-2650(19)32209-8. doi: 10.1016/j.clml.2019.11.019. [Epub ahead of print] Review.

PMID:
32019730
2.

Structured crowdsourcing enables convolutional segmentation of histology images.

Amgad M, Elfandy H, Hussein H, Atteya LA, Elsebaie MAT, Abo Elnasr LS, Sakr RA, Salem HSE, Ismail AF, Saad AM, Ahmed J, Elsebaie MAT, Rahman M, Ruhban IA, Elgazar NM, Alagha Y, Osman MH, Alhusseiny AM, Khalaf MM, Younes AF, Abdulkarim A, Younes DM, Gadallah AM, Elkashash AM, Fala SY, Zaki BM, Beezley J, Chittajallu DR, Manthey D, Gutman DA, Cooper LAD.

Bioinformatics. 2019 Sep 15;35(18):3461-3467. doi: 10.1093/bioinformatics/btz083.

3.

Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.

Lee JY, Schizas M, Geyer FC, Selenica P, Piscuoglio S, Sakr RA, Ng CKY, Carniello JVS, Towers R, Giri DD, de Andrade VP, Papanastasiou AD, Viale A, Harris RS, Solit DB, Weigelt B, Reis-Filho JS, King TA.

Clin Cancer Res. 2019 Jan 15;25(2):674-686. doi: 10.1158/1078-0432.CCR-18-1103. Epub 2018 Sep 5.

4.

Embryonic hematopoiesis modulates the inflammatory response and larval hematopoiesis in Drosophila.

Bazzi W, Cattenoz PB, Delaporte C, Dasari V, Sakr R, Yuasa Y, Giangrande A.

Elife. 2018 Jul 11;7. pii: e34890. doi: 10.7554/eLife.34890.

5.

Persistence of Yellow Fever Immunization-Induced Antibodies in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Adler M, Lapierre V, Sakr R, Bourhis JH, Gachot B, Castilla-Llorente C, Wyplosz B.

J Infect Dis. 2018 May 5;217(11):1844-1845. doi: 10.1093/infdis/jiy050. No abstract available.

PMID:
29547928
6.

Cervical cancer screening among Lebanese women.

Bou-Orm IR, Sakr RE, Adib SM.

Rev Epidemiol Sante Publique. 2018 Feb;66(1):1-6. doi: 10.1016/j.respe.2017.10.004. Epub 2017 Dec 14.

PMID:
29249573
7.

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

Sakr R, Renneville A, Saada V, Cotteret S, Martin JE, Droin N, Selimoglu-Buet D, Besse B, Hollebecque A, Marzac C, Pasquier F, Micol JB, De Botton S, Mir O, Solary E, Willekens C.

Leuk Lymphoma. 2018 Jul;59(7):1742-1745. doi: 10.1080/10428194.2017.1397669. Epub 2017 Nov 8. No abstract available.

PMID:
29115897
8.

Do Lumpectomy Cavity Shaved Margins Really Not Impact Re-excision Rates in Breast Cancer?

Bricou A, Sakr R, Barranger E.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):585. doi: 10.1245/s10434-017-6188-5. Epub 2017 Oct 24. No abstract available.

PMID:
29067601
9.

Contralateral breast cancers: Independent cancers or metastases?

Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS.

Int J Cancer. 2018 Jan 15;142(2):347-356. doi: 10.1002/ijc.31051. Epub 2017 Sep 28.

10.

Real-life Experience for Integration of PET-CT in the Treatment of Hodgkin Lymphoma in Lebanon.

Sakr R, Massoud M, Kerbage F, Rached L, Zeghondy J, Akoury E, Nasr F, Chahine G.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S92-S95. doi: 10.1016/j.clml.2017.03.295.

PMID:
28760308
11.

Survival Pattern of Hodgkin Lymphoma Patients in the Last 25 Years in Lebanon.

Massoud M, Kerbage F, Nehme J, Sakr R, Rached L, Zeghondy J, Nasr F, Chahine G.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S88-S91. doi: 10.1016/j.clml.2017.03.297.

PMID:
28760307
12.

Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.

Massoud M, Sakr R, Kerbage F, Makdissi J, Hawi J, Rached L, Nasr F, Chahine G.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S111-S115. doi: 10.1016/j.clml.2017.03.294.

PMID:
28760296
13.

Gastric Adenocarcinoma Secondary to Primary Gastric Diffuse Large B-cell Lymphoma.

Sakr R, Massoud M, Aftimos G, Chahine G.

J Gastric Cancer. 2017 Jun;17(2):180-185. doi: 10.5230/jgc.2017.17.e11. Epub 2017 Mar 22.

14.

Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review.

De Brot M, Koslow Mautner S, Muhsen S, Andrade VP, Mamtani A, Murray M, Giri D, Sakr RA, Brogi E, King TA.

Breast Cancer Res Treat. 2017 Sep;165(2):411-420. doi: 10.1007/s10549-017-4334-1. Epub 2017 Jun 13.

15.

Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.

Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN.

J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.

16.

Mucous Membrane Grafting Augmented with Topical Mitomycin C Application in Contracted Socket Repair Surgeries.

Mandour SS, Elmazar HM, Marey HM, Rahman AK, Sakr RA.

J Ocul Pharmacol Ther. 2016 Dec;32(10):691-694. Epub 2016 Nov 10.

PMID:
27830980
17.

Clonal relationships between lobular carcinoma in situ and other breast malignancies.

Begg CB, Ostrovnaya I, Carniello JV, Sakr RA, Giri D, Towers R, Schizas M, De Brot M, Andrade VP, Mauguen A, Seshan VE, King TA.

Breast Cancer Res. 2016 Jun 23;18(1):66. doi: 10.1186/s13058-016-0727-z.

18.

Prescription Errors with Chemotherapy: Quality Improvement through Standardized Order Templates.

Saad A, Der-Nigoghossian CA, Njeim R, Sakr R, Salameh P, Massoud M.

Asian Pac J Cancer Prev. 2016;17(4):2329-36.

19.

Adherence to Monitoring Tests in Patients With Chronic Myeloid Leukemia in Lebanon.

Massoud M, Nasr F, Sakr R, Hawi J, Kerbage F, Chahine G.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S101-4. doi: 10.1016/j.clml.2016.03.007. Epub 2016 Apr 4. Review.

PMID:
27220473
20.

The Genomic Landscape of Male Breast Cancers.

Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, Bidard FC, Berman S, Fusco N, Sakr RA, Eberle CA, De Mattos-Arruda L, Macedo GS, Akram M, Baslan T, Hicks JB, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS.

Clin Cancer Res. 2016 Aug 15;22(16):4045-56. doi: 10.1158/1078-0432.CCR-15-2840. Epub 2016 Mar 9.

21.

Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.

Guerini-Rocco E, Piscuoglio S, Ng CK, Geyer FC, De Filippo MR, Eberle CA, Akram M, Fusco N, Ichihara S, Sakr RA, Yatabe Y, Vincent-Salomon A, Rakha EA, Ellis IO, Wen YH, Weigelt B, Schnitt SJ, Reis-Filho JS.

J Pathol. 2016 Apr;238(5):677-88. doi: 10.1002/path.4691.

22.

Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

Jhaveri K, Chandarlapaty S, Iyengar N, Morris PG, Corben AD, Patil S, Akram M, Towers R, Sakr RA, King TA, Norton L, Rosen N, Hudis C, Modi S.

Clin Breast Cancer. 2016 Aug;16(4):276-83. doi: 10.1016/j.clbc.2015.11.004. Epub 2015 Nov 19.

23.

Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.

Sakr RA, Schizas M, Carniello JV, Ng CK, Piscuoglio S, Giri D, Andrade VP, De Brot M, Lim RS, Towers R, Weigelt B, Reis-Filho JS, King TA.

Mol Oncol. 2016 Feb;10(2):360-70. doi: 10.1016/j.molonc.2015.11.001. Epub 2015 Nov 14.

24.

Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile.

Eberle CA, Piscuoglio S, Rakha EA, Ng CK, Geyer FC, Edelweiss M, Sakr RA, Weigelt B, Reis-Filho JS, Ellis IO.

Histopathology. 2016 Jun;68(7):1030-9. doi: 10.1111/his.12897. Epub 2016 Jan 7.

25.

Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.

King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, Guerini-Rocco E, Boafo C, Gooch JC, De Brot M, Reis-Filho JS, Morrogh M, Andrade VP, Sakr RA, Morrow M.

J Clin Oncol. 2015 Nov 20;33(33):3945-52. doi: 10.1200/JCO.2015.61.4743. Epub 2015 Sep 14.

26.

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.

Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K.

Nat Genet. 2015 Oct;47(10):1212-9. doi: 10.1038/ng.3391. Epub 2015 Aug 24.

27.

Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.

Bidard FC, Ng CK, Cottu P, Piscuoglio S, Escalup L, Sakr RA, Reyal F, Mariani P, Lim R, Wang L, Norton L, Servois V, Sigal B, Vincent-Salomon A, Weigelt B, Pierga JY, Reis-Filho JS.

Ann Oncol. 2015 Aug;26(8):1704-9. doi: 10.1093/annonc/mdv217. Epub 2015 May 7.

28.

Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion.

Andrade VP, Morrogh M, Qin LX, Olvera N, Giri D, Muhsen S, Sakr RA, Schizas M, Ng CK, Arroyo CD, Brogi E, Viale A, Morrow M, Reis-Filho JS, King TA.

Mol Oncol. 2015 Apr;9(4):772-82. doi: 10.1016/j.molonc.2014.12.005. Epub 2014 Dec 24.

29.

Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands.

Weinreb I, Piscuoglio S, Martelotto LG, Waggott D, Ng CK, Perez-Ordonez B, Harding NJ, Alfaro J, Chu KC, Viale A, Fusco N, da Cruz Paula A, Marchio C, Sakr RA, Lim R, Thompson LD, Chiosea SI, Seethala RR, Skalova A, Stelow EB, Fonseca I, Assaad A, How C, Wang J, de Borja R, Chan-Seng-Yue M, Howlett CJ, Nichols AC, Wen YH, Katabi N, Buchner N, Mullen L, Kislinger T, Wouters BG, Liu FF, Norton L, McPherson JD, Rubin BP, Clarke BA, Weigelt B, Boutros PC, Reis-Filho JS.

Nat Genet. 2014 Nov;46(11):1166-9. doi: 10.1038/ng.3096. Epub 2014 Sep 21.

30.

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Sakr RA, Weigelt B, Chandarlapaty S, Andrade VP, Guerini-Rocco E, Giri D, Ng CK, Cowell CF, Rosen N, Reis-Filho JS, King TA.

Clin Cancer Res. 2014 May 1;20(9):2326-37. doi: 10.1158/1078-0432.CCR-13-2267. Epub 2014 Mar 14.

31.

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S.

Nat Genet. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3.

32.

Is there a role for routine screening MRI in women with LCIS?

King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M.

Breast Cancer Res Treat. 2013 Nov;142(2):445-53. doi: 10.1007/s10549-013-2725-5. Epub 2013 Oct 19.

33.

Progression from ductal carcinoma in situ to invasive breast cancer: revisited.

Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, Reis-Filho JS.

Mol Oncol. 2013 Oct;7(5):859-69. doi: 10.1016/j.molonc.2013.07.005. Epub 2013 Jul 12. Review.

34.

[Does molecular biology play any role in ductal carcinoma in situ?].

Sakr RA.

Gynecol Obstet Fertil. 2013 Jan;41(1):45-53. doi: 10.1016/j.gyobfe.2012.11.004. Epub 2012 Dec 31. French.

PMID:
23286959
35.

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.

Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA.

Clin Cancer Res. 2012 Dec 15;18(24):6784-91. doi: 10.1158/1078-0432.CCR-12-1785. Epub 2012 Oct 23.

36.

Impact of immunohistochemical analysis of sentinel lymph node biopsy on breast cancer management.

Chéreau E, Bezu C, Gligorov J, Sakr R, Antoine M, Daraï E, Uzan S, Rouzier R.

Anticancer Res. 2012 Aug;32(8):3403-9.

PMID:
22843922
37.

Can the centrosome be a marker for DNA ploidy in breast cancer?

Sakr RA, Fleury J, Prengel C, Bernaudin JF, Uzan S, Rouzier R, Darai E.

J Cytol. 2012 Apr;29(2):111-5. doi: 10.4103/0970-9371.97150.

38.

Genomic complexity and AKT dependence in serous ovarian cancer.

Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She QB, Aghajanian C, King TA, Stanchina Ed, Spriggs DR, Heguy A, Taylor BS, Sander C, Rosen N, Levine DA, Solit DB.

Cancer Discov. 2012 Jan;2(1):56-67. doi: 10.1158/2159-8290.CD-11-0170. Erratum in: Cancer Discov. 2012 Apr;2(4):376. Janikariman, Manickam [corrected to Janakiraman, Manickam].

39.

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Janavicius R, Tihomirova L, Hansen TV, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB; HEBON, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C; EMBRACE, Weaver J, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, Stoppa-Lyonnet D, Belotti M, Barjhoux L; GEMO Study Collaborators, Isaacs C, Peshkin BN, Caldes T, de la Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S; kConFab Investigators, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea MK, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes AM, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K; SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum R, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC; Consortium of Investigators of Modifiers of BRCA1/2.

Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47. doi: 10.1158/1055-9965.EPI-11-0775. Epub 2011 Dec 5.

40.

Cadherin-catenin complex dissociation in lobular neoplasia of the breast.

Morrogh M, Andrade VP, Giri D, Sakr RA, Paik W, Qin LX, Arroyo CD, Brogi E, Morrow M, King TA.

Breast Cancer Res Treat. 2012 Apr;132(2):641-52. doi: 10.1007/s10549-011-1860-0. Epub 2011 Nov 13.

41.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.

Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, Janavicius R, Hansen Tv, Nielsen FC, Ejlertsen B, Osorio A, Muñoz-Repeto I, Durán M, Godino J, Pertesi M, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Bonanni B, Viel A, Pasini B, Papi L, Ottini L, Savarese A, Bernard L, Radice P, Hamann U, Verheus M, Meijers-Heijboer HE, Wijnen J, Gómez García EB, Nelen MR, Kets CM, Seynaeve C, Tilanus-Linthorst MM, van der Luijt RB, van Os T, Rookus M, Frost D, Jones JL, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Cook J, Donaldson A, Dorkins H, Gregory H, Eason J, Houghton C, Barwell J, Side LE, McCann E, Murray A, Peock S, Godwin AK, Schmutzler RK, Rhiem K, Engel C, Meindl A, Ruehl I, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Kast K, Preisler-Adams S, Varon-Mateeva R, Schoenbuchner I, Fiebig B, Heinritz W, Schäfer D, Gevensleben H, Caux-Moncoutier V, Fassy-Colcombet M, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Hardouin A, Berthet P, Muller D, Fricker JP, Mortemousque I, Pujol P, Coupier I, Lebrun M, Kientz C, Longy M, Sevenet N, Stoppa-Lyonnet D, Isaacs C, Caldes T, de la Hoya M, Heikkinen T, Aittomäki K, Blanco I, Lazaro C, Barkardottir RB, Soucy P, Dumont M, Simard J, Montagna M, Tognazzo S, D'Andrea E, Fox S, Yan M, Rebbeck T, Olopade O, Weitzel JN, Lynch HT, Ganz PA, Tomlinson GE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet M, Bhatia J, Kauff N, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Mai PL, Greene MH, Imyanitov E, O'Malley FP, Ozcelik H, Glendon G, Toland AE, Gerdes AM, Thomassen M, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Soller M, Henriksson K, Wachenfeldt vA, Arver B, Stenmark-Askmalm M, Karlsson P, Ding YC, Neuhausen SL, Beattie M, Pharoah PD, Moysich KB, Nathanson KL, Karlan BY, Gross J, John EM, Daly MB, Buys SM, Southey MC, Hopper JL, Terry MB, Chung W, Miron AF, Goldgar D, Chenevix-Trench G, Easton DF, Andrulis IL, Antoniou AC; Breast Cancer Family Registry; EMBRACE; GEMO Study Collaborators; HEBON; kConFab Investigators; Ontario Cancer Genetics Network; SWE-BRCA; CIMBA.

Breast Cancer Res. 2011;13(6):R110. doi: 10.1186/bcr3052. Epub 2011 Nov 2.

42.

Is there a low-grade precursor pathway in breast cancer?

King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M.

Ann Surg Oncol. 2012 Apr;19(4):1115-21. doi: 10.1245/s10434-011-2053-0. Epub 2011 Sep 21.

PMID:
21935747
43.

Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.

Morrogh M, Andrade VP, Patil AJ, Qin LX, Mo Q, Sakr R, Arroyo CD, Brogi E, Morrow M, King TA.

J Surg Res. 2012 Jul;176(1):121-32. doi: 10.1016/j.jss.2011.05.058. Epub 2011 Jun 25.

44.

Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.

King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M.

J Clin Oncol. 2011 Jun 1;29(16):2158-64. doi: 10.1200/JCO.2010.29.4041. Epub 2011 Apr 4.

PMID:
21464413
45.

[Are centrosomal abnormalities correlated to DNA ploidy in breast cancer?].

Sakr R, Fleury J, Prengel C, Roynard P, Daraï E, Uzan S, Rouzier R, Bernaudin JF.

Ann Biol Clin (Paris). 2011 Mar-Apr;69(2):181-9. doi: 10.1684/abc.2011.0525. French.

46.

Occult malignancy in patients undergoing contralateral prophylactic mastectomy.

King TA, Gurevich I, Sakr R, Patil S, Stempel M, Morrow M.

Ann Surg. 2011 Jul;254(1):2-7. doi: 10.1097/SLA.0b013e3182125b26.

PMID:
21372684
47.

Clear margins for invasive lobular carcinoma: a surgical challenge.

Sakr RA, Poulet B, Kaufman GJ, Nos C, Clough KB.

Eur J Surg Oncol. 2011 Apr;37(4):350-6. doi: 10.1016/j.ejso.2011.01.010. Epub 2011 Feb 1.

PMID:
21277728
48.

Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.

Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N, King TA.

Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):371-4. doi: 10.1097/PAI.0b013e3181d50bd5.

49.

Silicone migration to the contralateral axillary lymph nodes and breast after highly cohesive silicone gel implant failure: a case report.

Kaufman GJ, Sakr RA, Inguenault C, Sarfati I, Nos C, Clough KB.

Cases J. 2009 Mar 10;2:6420. doi: 10.1186/1757-1626-2-6420.

50.

Uterine adenosarcoma associated to lymphovascular emboli: a case report.

Sakr R, Marzouk P, Bricou A, Demaria F, Cortez A, Benifla JL.

Cases J. 2009 May 18;2:7515. doi: 10.1186/1757-1626-2-7515.

Supplemental Content

Support Center